Richard F Schlenk

发表

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

Claudio Lottaz, Stefan Fröhling, Jonathan R Pollack, 2007 .

Is there justification for 4 cycles of consolidation therapy in AML?

R. Schlenk, Richard F Schlenk, 2016, Best practice & research. Clinical haematology.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Manuela Zucknick, Verena I Gaidzik, Lars Bullinger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Axel Benner, Stefan Fröhling, Lars Bullinger, 2008, The New England journal of medicine.

Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization.

Stefan Fröhling, Bernhard Radlwimmer, Peter Lichter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Precision oncology for acute myeloid leukemia using a knowledge bank approach

Inigo Martincorena, Verena I Gaidzik, Peter J Campbell, 2017, Nature Genetics.

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.

Robert Tibshirani, Stefan Fröhling, Jonathan R Pollack, 2008, Blood.

High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.

Lars Bullinger, Christian Buske, Wolfgang Hiddemann, 2012, Blood.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Erdogan Taskesen, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Axel Benner, Stefan Fröhling, Hartmut Döhner, 2002, Blood.

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.

Axel Benner, Peter Lichter, Dirk Winkler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling

Axel Benner, Harald Binder, Martin Schumacher, 2016, PloS one.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Filippo Castiglione, Fabrizio Stracci, Torsten Haferlach, 2008, Haematologica.

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

Verena I Gaidzik, Lars Bullinger, Hartmut Döhner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Stefan Fröhling, Lars Bullinger, Claudia Scholl, 2005, Blood.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia

Lars Bullinger, Hans A Kestler, Hartmut Döhner, 2011, Haematologica.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Paola Fazi, Marco Vignetti, Giuseppe Avvisati, 2013, The New England journal of medicine.

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.

Verena I Gaidzik, Thomas Schroeder, Thomas Kindler, 2019, Blood.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Michael Stadler, Verena I Gaidzik, Michael Heuser, 2018, Blood.

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Verena I Gaidzik, Lars Bullinger, Brigitte Schlegelberger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

Roland Eils, David Bonekamp, Kortine Kleinheinz, 2019, Nature Communications.